Bone marrow derived mesenchymal stem cell therapy - Taiwan Bio Therapeutics
Alternative Names: BM-MSCs - Taiwan Bio Therapeutics; Bone marrow mesenchymal stem cells - Taiwan Bio Therapeutics; Chondrochymal®Latest Information Update: 29 Oct 2021
Price :
$50 *
At a glance
- Originator Taiwan Bio Therapeutics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 15 Sep 2021 Phase-II clinical trials in Osteoarthritis (Treatment-experienced) in Taiwan (Intra-articular) (NCT05027581)
- 30 Aug 2021 Taiwan Bio Therapeutics plans phase IIb trial for Osteoarthritis (Treatment-experienced) in September 2021 (Intra-articular, Injection) (NCT05027581)
- 31 Dec 2020 Taiwan Bio Therapeutics submits Clinical Study Report (CSR) of phase I/IIa trial for Osteoarthritis to Taiwan Food Drug Administration (TFDA) by 2020 (Taiwan Bio therapeutics website, September 2021)